Anticancer Drugs (TS-1, Taxanes, CPT-11, Platinum-Containing Drugs, Etc.)

The risk of drug-induced lung injuries at the clinically trial step is considered to be relatively high with irinotecan hydrochloride, vinorelbine tartrate, gemcitabine hydrochloride, and amrubicin hydrochloride (Table 10.1). The number of cases will be insufficient to understand low-frequency adverse drug reactions such as drug-induced lung injuries in a clinical trial, and usually, this information is confirmed in a post-marketing survey. Although post-marketing all-case surveys have recently been conducted for many molecular-targeted drugs in Japan, drugs which had been developed before were investigated in ordinary post-marketing surveys or were self-reported data.